Experimental blood cancer drug trial halted early – what happened?
NCT ID NCT05086315
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tested a new drug called SAR443579 in adults and children with hard-to-treat blood cancers like acute myeloid leukemia and acute lymphoblastic leukemia. The goal was to see if the drug was safe and could shrink or eliminate cancer. The trial was stopped early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center-Site Number:8400004
Boston, Massachusetts, 02215, United States
-
City of Hope-Site Number:8400002
Duarte, California, 91010, United States
-
Emory University School of Medicine- Grady Campus- Site Number : 8400006
Atlanta, Georgia, 30303, United States
-
Investigational Site Number : 1560001
Tianjin, 300020, China
-
Investigational Site Number : 1560003
Zhengzhou, 450008, China
-
Investigational Site Number : 2500004
Paris, 75019, France
-
Investigational Site Number : 5280005
Nijmegen, 6525 GA, Netherlands
-
Investigational Site Number :0360001
Melbourne, Victoria, 3004, Australia
-
Investigational Site Number :0360002
Melbourne, Victoria, 3000, Australia
-
Investigational Site Number :2500001
Paris, 75010, France
-
Investigational Site Number :2500002
Marseille, 13009, France
-
Investigational Site Number :2500003
Villejuif, 94800, France
-
Investigational Site Number :5280001
Rotterdam, 3015 CE, Netherlands
-
Investigational Site Number :5280002
Amsterdam, 1081 HV, Netherlands
-
Investigational Site Number :5280003
Groningen, 9713 GZ, Netherlands
-
Investigational Site Number :5280004
Utrecht, 3584 CS, Netherlands
-
MD Anderson Cancer Center-Site Number:8400001
Houston, Texas, 77030, United States
-
Montefiore Hutchinson Campus- Site Number : 8400012
The Bronx, New York, 10461, United States
-
Oregon Health and Science University-Site Number:8400011
Portland, Oregon, 97239, United States
-
Seattle Children's Hospital- Site Number : 8400014
Seattle, Washington, 98105, United States
-
The Children's Hospital of Philadelphia- Site Number : 8400013
Philadelphia, Pennsylvania, 19104, United States
-
The Ohio State University- Site Number : 8400009
Columbus, Ohio, 43210, United States
-
Weill Cornell Medical College-Site Number:8400003
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.